This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Uber Is Formally into the Staffing Business
by Sejuti Banerjea
Uber Works makes Uber more like the technology platform it claims to be and less the ride-hailing service that we recognize it as.
New Strong Buy Stocks for December 19th
by Tirthankar Chakraborty
Here are 3 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
New Strong Buy Stocks for December 16th
by Tirthankar Chakraborty
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZYNE) Outperforming Other Medical Stocks This Year?
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Zynerba Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Generic Drugs Industry Turns the Corner on Price Stabilization
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs are leading to recovery in the industry. New launches are also a boost. However, competition remains stiff.
Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $7.44, marking a -0.53% move from the previous day.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Zynerba Pharmaceuticals (ZYNE) Stock Moves -1.43%: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $7.26 in the latest trading session, marking a -1.43% move from the prior day.
Epidolex Progresses: Will the Marijuana Drug Market Boom?
by Indrajit Bandyopadhyay
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.
Zynerba Releases Data on Epilepsy Candidate, Stock Down
by Zacks Equity Research
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Zynerba (ZYNE) Meets Earnings Estimates in Q2, Revenues Nil
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) reported in-line with market expectation in the second quarter with earnings meeting estimates.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $11.87, marking a +1.63% move from the previous day.
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $14.40 in the latest trading session, marking a +0.7% move from the prior day.
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $14.24 in the latest trading session, marking a +0.92% move from the prior day.
Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $12.48 in the latest trading session, marking a -0.56% move from the prior day.
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $13.91, moving +0.87% from the previous trading session.
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $13.52, moving +0.15% from the previous trading session.
Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
by Zacks Equity Research
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZYNE) Outperforming Other Medical Stocks This Year?
Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals, Inc. (ZYNE).
Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZYNE) Outperforming Other Medical Stocks This Year?